Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
301
datasets available to search
ShareScore release 0.9.0
Dataset results
301 results for “sitagliptin”
Figure 4 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 4 H&E (200×) of rat kidneys from: A. control showing normal renal histology; B, C. 5-fluorouracil (5-FU) group demonstrating marked distortion of kidney architecture, renal tubular necrosis and dilatation, desquamation of lining epithelium (black arrows), interstitial edema, areas of coagulative necrosis (white arrow), and inflammatory cell infiltration (black head); D, E. sitagliptin (SIT 5 mg/kg) + 5-FU and (SIT 10 mg/kg) + 5-FU, respectively, showing preservation of the normal kidney architecture; F. tubular injury score. *p < 0.05 vs. control, ≠p < 0.05 vs. 5FU. Results are mean ± S.E.M., n = 8, in each group.
Figure 2 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 2 Effects of sitagliptin (SIT) treatment on malondialdehyde (MDA) and total antioxidant capacity (TAC) in kidneys of 5-fluorouracil (5-FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
Figure 3 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 3 Effects of sitagliptin (SIT) treatment on: A. Nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor- κB p65 (NF-κB p65); B. Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β); C. Bax/Bcl-2 ratio and cleaved caspases-3 in kidneys of 5-fluorouracil (5FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
Figure 1 from: Al-Ghamdi AH, Mohamed MZ, Elbadry RM, Fouad AA (2024) Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e114441
Figure 1 Effects of sitagliptin (SIT) treatment on serum creatinine (Cr) and neutrophil gelatinaseassociated lipocalin (NGAL) of 5-fluorouracil (5-FU)-challenged rats. *p < 0.05 vs. control, ≠p < 0.05 vs. 5-FU group. Results are mean ± S.E.M, n = 8, in each group.
Figure 4 from: Bozhanov S, Smerikarova M, Maslarska V (2024) Simultaneous HPLC determination of remdesivir and dexamethasone in the presence of metformin, sitagliptin, and glimepiride in a synthetic mixture and spiked human plasma. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e120463
Figure 4 Representative chromatograms obtained from A. The blank and B. Spiked plasma samples. Legend: Peak numbers: DXM-2, STG-3, RDV-4 and GLM-5.
Figure 3 from: Bozhanov S, Smerikarova M, Maslarska V (2024) Simultaneous HPLC determination of remdesivir and dexamethasone in the presence of metformin, sitagliptin, and glimepiride in a synthetic mixture and spiked human plasma. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e120463
Figure 3 Representative chromatograms obtained from A. The mobile phase and B. Synthetic mixture. Legend: Peak numbers: MTF-1, DXM-2, STG-3, RDV-4, and GLM-5.
A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)
ClinicalTrials.gov study NCT00975052. IPD Sharing: Not stated. Countries: 0. Publications: 1.
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
ClinicalTrials.gov study NCT03267576. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
ClinicalTrials.gov study NCT01408888. IPD Sharing: Not stated. Countries: 1. Publications: 0.
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
ClinicalTrials.gov study NCT00666458. IPD Sharing: Not stated. Countries: 9. Publications: 0.
Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
ClinicalTrials.gov study NCT01970462. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
ClinicalTrials.gov study NCT02556918. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
ClinicalTrials.gov study NCT02956044. IPD Sharing: NO. Countries: 1. Publications: 0.
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With T
ClinicalTrials.gov study NCT02284893. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery
ClinicalTrials.gov study NCT02443402. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese
ClinicalTrials.gov study NCT01610154. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sitagliptin for Reducing Inflammation and Immune Activation
ClinicalTrials.gov study NCT02513771. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
ClinicalTrials.gov study NCT01490918. IPD Sharing: NO. Countries: 1. Publications: 0.
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
ClinicalTrials.gov study NCT00484419. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Use of Sitagliptin to Decrease Microalbuminuria
ClinicalTrials.gov study NCT02048904. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.